"The results of the present study largely increased the feasibility of nitroxoline repurposing for clinical anticancer application, particularly for bladder cancer treatment.

In summary, the current study demonstrated that nitroxoline and its metabolite nitroxoline sulfate in the urine exhibit powerful anti-cancer potential against urological tumors, and the routine nitroxoline administration regimen for human UTI treatment appeared to be effective and sufficient for urological cancer treatment. These results, in addition to the well-known safety profiles of nitroxoline and well‑defined pharmacokinetic properties, successfully advanced nitroxoline repurposing into a phase II clinical trial in China for non-muscle invasive bladder cancer treatment (registration no. CTR20131716)."

https://pdfs.semanticscholar.org/2cac/fa558aeefa51c41964d4b0d29e11d366f017.pdf